Table 1.
Demographic and clinical data of the ICON study population
| ICON patients with 25(OH)D measurement | All patients of the ICON study | |
|---|---|---|
| Number | 360 | 954 |
| Female (%) | 67.5 | 67.2 |
| Age at study inclusion, years, mean (SD) | 7.1 (4.6) | 7.9 (4.8) |
| Duration between symptom onset and diagnosis, months, median (IQR) | 3 (2–7) | 3 (1–6) |
| Duration between diagnosis and ICON enrollment, months, median (IQR) | 1.4 (0.5–4.4) | 1.5 (0.4–4.7) |
| Patients | ||
| - on DMARD at inclusion, n (%) | 178 (49) | 471 (49) |
| - on MTX at inclusion, n (%) | 164 (46) | 441 (46) |
| - on biologic drug at inclusion, n (%) | 14 (4) | 49 (5) |
| Median (IQR) duration (months) of | ||
| - DMARD use at inclusion | 1.2 (0.5–3.4) | 1.2 (0.5–3.5) |
| - MTX use at inclusion | 1.2 (0.5–3.5) | 1.2 (0.5–3.4) |
| - Biologic drug use at inclusion | 1.1 (0.4–2.9) | 0.9 (0.3–2.9) |
| ANA positive at study inclusion, n (%) | 228 (63) | 517 (54) |
| ILAR category, n (%) | ILAR category, n (%) | |
| Systemic arthritis | 15 (4) | 35 (4) |
| Oligoarthritis | 173 (48) | 445 (47) |
| Psoriatic arthritis | 18 (5) | 39 (4) |
| Enthesitis-related arthritis | 30 (8) | 100 (11) |
| Polyarthritis, rheumatoid factor positive | 5 (1) | 15 (2) |
| Polyarthritis, rheumatoid factor negative | 96 (27) | 252 (26) |
| Other arthritis | 23 (6) | 68 (7) |
ICON Inception cohort of newly diagnosed patients with juvenile idiopathic arthritis, 25(OH)D: 25(OH) vitamin D, SD standard deviation, IQR interquartile range, DMARD disease-modifying antirheumatic drug, MTX methotrexate, ANA antinuclear antibody, ILAR International League of Associations for Rheumatology